Neonc Technologies Holdings, Inc.(NTHI)

Biotechnology · Calabasas, CA

$2.99+0.07 (+2.40%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T21:52:38.460Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:52:38.460Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 77,536,279
Total debt · period ending 2026-06-30: 328,217
Cash · period ending 2026-06-30: 1,973,420
TTM operating EBITDA · period ending 2026-06-30: -41,681,295

FMP input reference: 2d3a9198413857e44d8ff08287218970dc762668c083e85858692cc7a401d48f

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NTHI EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

NTHI Competitors' EV/EBITDA Ratio

NTHI

Neonc Technologies Holdings, Inc.

Current

Market Cap

$77.54M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INO

Inovio Pharmaceuticals, Inc.

vs NTHI

Market Cap

$78.07M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SERA

Sera Prognostics, Inc.

vs NTHI

Market Cap

$78.29M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Outset Medical, Inc.

vs NTHI

Market Cap

$76.74M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VTVT

vTv Therapeutics Inc.

vs NTHI

Market Cap

$78.59M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTOR

Citius Oncology, Inc.

vs NTHI

Market Cap

$79.03M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SKIN

SkinHealth Systems Inc.

vs NTHI

Market Cap

$75.95M

EV/EBITDA Ratio

10.31x

TTM Avg

27.31x

3Y Avg

27.31x

5Y Avg

27.31x

ACRV

Acrivon Therapeutics, Inc. Common Stock

vs NTHI

Market Cap

$79.61M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUNG

Pulmonx Corporation

vs NTHI

Market Cap

$75.18M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HUMA

Humacyte, Inc.

vs NTHI

Market Cap

$80.30M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Neonc Technologies Holdings, Inc. (NTHI)	$77.54M	N/A	N/A	N/A	N/A
Inovio Pharmaceuticals, Inc. (INO)vs ›	$78.07M	N/A	N/A	N/A	N/A
Sera Prognostics, Inc. (SERA)vs ›	$78.29M	N/A	N/A	N/A	N/A
Outset Medical, Inc. (OM)vs ›	$76.74M	N/A	N/A	N/A	N/A
vTv Therapeutics Inc. (VTVT)vs ›	$78.59M	N/A	N/A	N/A	N/A
Citius Oncology, Inc. (CTOR)vs ›	$79.03M	N/A	N/A	N/A	N/A
SkinHealth Systems Inc. (SKIN)vs ›	$75.95M	10.31x	27.31x	27.31x	27.31x
Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›	$79.61M	N/A	N/A	N/A	N/A
Pulmonx Corporation (LUNG)vs ›	$75.18M	N/A	N/A	N/A	N/A
Humacyte, Inc. (HUMA)vs ›	$80.30M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics